Morita M - Search Results

1

Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy.

Nishimura S, Saeki H, Nakanoko T, Kasagi Y, Tsuda Y, Zaitsu Y, Ando K, Nakashima Y, Imamura YU, Ohgaki K, Oki E, Ohga S, Nakamura K, Morita M, Maehara Y. Nishimura S, et al. Among authors: morita m. Anticancer Res. 2015 Apr;35(4):2299-303. Anticancer Res. 2015. PMID: 25862892

2

Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract.

Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K. Morita M, et al. Surgery. 2002 Jan;131(1 Suppl):S1-6. doi: 10.1067/msy.2002.119287. Surgery. 2002. PMID: 11821780 Review.

3

p53 protein accumulation in multiple oesophageal squamous cell carcinoma: relationship to risk factors.

Saeki H, Ohno S, Miyazaki M, Araki K, Egashira A, Kawaguchi H, Watanabe M, Morita M, Sugimachi K. Saeki H, et al. Among authors: morita m. Oncology. 2002;62(2):175-9. doi: 10.1159/000048264. Oncology. 2002. PMID: 11914604

4

Risk factors for multicentric occurrence of carcinoma in the upper aerodigestive tract-analysis with a serial histologic evaluation of the whole resected-esophagus including carcinoma.

Morita M, Araki K, Saeki H, Sakaguchi Y, Baba H, Sugimachi K, Yano K, Sugio K, Yasumoto K. Morita M, et al. J Surg Oncol. 2003 Aug;83(4):216-21. doi: 10.1002/jso.10276. J Surg Oncol. 2003. PMID: 12884233

5

Considerable multiple esophageal carcinoma. Implications of a new clinical entity.

Kuwano H, Egashira A, Araki K, Saeki H, Kawaguchi H, Morita M, Kitamura K, Sugimachi K. Kuwano H, et al. Among authors: morita m. Hepatogastroenterology. 2004 Nov-Dec;51(60):1713-6. Hepatogastroenterology. 2004. PMID: 15532811

6

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.

Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y. Tokunaga E, et al. Among authors: morita m. Eur J Cancer. 2006 Mar;42(5):629-35. doi: 10.1016/j.ejca.2005.11.025. Epub 2006 Feb 7. Eur J Cancer. 2006. PMID: 16464571

7

Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.

Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, Kojima A, Egashira A, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Among authors: morita m. Breast Cancer Res Treat. 2006 May;97(2):199-203. doi: 10.1007/s10549-005-9112-9. Epub 2006 Feb 24. Breast Cancer Res Treat. 2006. PMID: 16502017

8

Activation of PI3K/Akt signaling and hormone resistance in breast cancer.

Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y. Tokunaga E, et al. Among authors: morita m. Breast Cancer. 2006;13(2):137-44. doi: 10.2325/jbcs.13.137. Breast Cancer. 2006. PMID: 16755107 Free article.

9

Expression of FHIT in esophageal epithelium and carcinoma: reference to drinking, smoking and multicentric carcinogenesis.

Morita M, Oyama T, Nakata S, Ono K, Sugaya M, Uramoto H, Yoshimatsu T, Hanagiri T, Sugio K, Yasumoto K. Morita M, et al. Anticancer Res. 2006 May-Jun;26(3B):2243-8. Anticancer Res. 2006. PMID: 16821595 Free article.

10

Trastuzumab and breast cancer: developments and current status.

Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Among authors: morita m. Int J Clin Oncol. 2006 Jun;11(3):199-208. doi: 10.1007/s10147-006-0575-4. Int J Clin Oncol. 2006. PMID: 16850126 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,600 results

Search Page

Filters